Mcule
- Company typePrivate
- Founded2014
- HeadquartersBudapest, Hungary
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Mcule firmographics
Firmographics- Name
- Mcule
- Legal name
- mcule.com Kft.
- Website
- https://mcule.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Where Mcule is headquartered
LocationHeadquarters
- HQ city
- Budapest
- HQ country
- Hungary
- HQ region
- Europe
Offices3 records
Markets served
Mcule business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Subscription Plans: Tiered subscription model providing access to premium features including Instant Quote, Product Filters, and Supplier Data Downloads. Free tier available with limited basic tools access.
- Compound Sourcing/Procurement: Transaction-based revenue from procurement and delivery of chemical compounds sourced from multiple suppliers, consolidated into single-package delivery.
- Database Downloads: Subscription-based access to download supplier data including catalog names, purity, and stock availability for all purchasable compounds.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Pay-as-you-go | Free Package - Basic hit identification and lead optimization tools |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Mcule product offering
Product offeringCore offering
Mcule operates a cloud-based drug discovery platform that integrates the purchasable chemical space with molecular modeling tools. It offers three core modules — Hit Identification (virtual screening workflows and 1-Click Docking), Compound Sourcing (a curated database of 140M+ purchasable compounds with automated price optimization and consolidated single-package delivery), and Lead Optimization (property calculation and toxicity assessment). The platform is delivered as a self-serve web service with free and paid subscription tiers.
Product overview
Mcule is a cloud-based drug discovery platform that integrates purchasable chemical space with molecular modeling tools. The platform consists of three core modules: Hit Identification (virtual screening and workflow builder for finding new chemical starting points), Compound Sourcing (high-quality database with 140M+ purchasable compounds, Instant Quote, and automated price optimization), and Lead Optimization (1-Click Docking, Property Calculator, and Toxicity Checker for compound evaluation). The platform also offers specialized compound libraries (ULTIMATE, Natural Products, Building Blocks, Fragments, Kinase, GPCR, CNS, RNA-Binding, and others), Mcule KNIME nodes for workflow integration, and a Research Accelerator Program for academic users. Mcule serves pharmaceutical and biotech companies along with academic researchers, providing both free tier and subscription-based access to increasingly powerful tools.
Differentiator
Problem solved
Functional benefit
Brands
- ULTIMATE Database: High-quality purchasable compound database including ULTIMATE Express catalog with over 111 million compounds
- MAC (mcule Advanced Curation)
- Research Accelerator Program
Products and services
- Mcule Online Drug Discovery Platform Integrated online platform combining purchasable chemical compound database with molecular modeling tools, enabling scientists to identify, optimize and order hits and leads for drug discovery projects.
- Hit Identification / Virtual Screening
Quantifiable outcome
- 40% hit rate reported - 40% of initially tested compounds bound to target protein with high affinity
- +2 more outcomes
Companies that use Mcule
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Mcule technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability3 records
Feature7 records
Mcule partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, flagship and minor.
- ChemaxoncoreChemaxon provides chemical software development platforms and desktop applications for biotech and pharmaceutical industries. They offer leading-edge cross-platform solutions for cheminformatics and chemical communication.
- AtomwisecoreAtomwise revolutionizes drug discovery with AI using deep learning for structure-based drug discovery. Their AtomNet technology has been used to unlock more undruggable targets than any other AI drug discovery platform.
- OpenEye ScientificcoreIndustry leader in computational molecular design based on decades of delivering rapid, robust, and scalable software and toolkits. Now integrated into Orion cloud-native molecular design platform.
- Schrödinger LiveDesigncoreSchrödinger's cloud-based enterprise informatics platform bringing together live cheminformatic data analysis and high throughput predictive modeling for accelerated molecular discovery projects.
- Cresset DiscoverycorePremier computational chemistry CRO with proven track record delivering high impact drug discovery projects. Integration of Mcule's purchasable compound library in Cresset Discovery's Blaze virtual screening platform provides greater chemical diversity for customers.
- European UnionflagshipEuropean Union funding for ULTIMATE project - a major database initiative to create ultra-large purchasable compound catalogs for virtual screening.
- WuXi TIDESminorWuXi AppTec's CRDMO providing solutions for nucleic acids, peptides, and related synthetic conjugates. Offers 3,000+ catalog TIDES building blocks including nucleotides and Fmoc-amino acids.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Mcule competitors and assessment
Company assessmentBroad incumbents
- Enamine: Ukraine-based, privately held large-scale provider of building blocks, screening compounds (REAL database with billions of virtual compounds), and custom synthesis. Largest direct competitor in compound database scale; broader product portfolio than Mcule.
- Dotmatics: Scientific R&D informatics platform providing data management, ELN, and chemistry tools for pharma/biotech. Broader incumbent with overlapping enterprise cheminformatics and drug discovery data management use cases.
- ChemAxon: Hungary-headquartered cheminformatics software platform providing chemical drawing, search, registration, and database infrastructure for pharma/biotech. Mcule partner and overlapping Hungarian roots, but broader enterprise software scope.
- Schrödinger: Publicly traded computational chemistry and drug discovery software platform with LiveDesign, FEP+, and a broad pharma customer base. Broad incumbent in the cheminformatics space; also a Mcule partner, but with overlapping virtual screening capability.
- OpenEye Scientific (Cadence Molecular Sciences): Computational chemistry software (Orion platform) serving pharma R&D with molecular design, docking, and cheminformatics tools. Mcule partner but also a broad incumbent with overlapping virtual screening and cheminformatics offerings.
Emerging players
- Atomwise: AI-driven structure-based drug discovery platform using deep learning (AtomNet) to identify novel compounds. Mcule partner but emerging AI-native competitor that may bypass traditional compound databases; overlap with Mcule's virtual screening customer base.
- Collaborative Drug Discovery (CDD): Cloud-based drug discovery informatics platform (CDD Vault) providing compound registration, screening data management, and collaboration tools for academic and biotech researchers. Emerging player with overlapping academic/biotech customer segment and cheminformatics focus.
Direct peers
- eMolecules: US-based chemical compound sourcing platform aggregating catalogs from hundreds of suppliers with substructure search and procurement workflow. Direct peer to Mcule's compound sourcing business with overlapping pharma/biotech customer base.
- ChemSpace: Compound marketplace providing search, pricing, and procurement across building blocks, screening libraries, and custom synthesis. Direct peer to Mcule's compound sourcing and catalog aggregation offering.
- MolPort: Latvia-based online compound sourcing marketplace aggregating catalogs from 80+ suppliers with chemical search and procurement tools. Most direct peer to Mcule's compound marketplace business, with comparable supplier aggregation and search UX.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Mcule social profiles
Digital presenceMcule financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mcule leadership team
Management profileNumber of profiles
Profiles12 records
Mcule funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mcule M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mcule
What does Mcule do?
Mcule operates a cloud-based drug discovery platform that integrates the purchasable chemical space with molecular modeling tools. It offers three core modules — Hit Identification (virtual screening workflows and 1-Click Docking), Compound Sourcing (a curated database of 140M+ purchasable compounds with automated price optimization and consolidated single-package delivery), and Lead Optimization (property calculation and toxicity assessment). The platform is delivered as a self-serve web service with free and paid subscription tiers.
Is Mcule a public or private company?
Mcule is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Mcule founded?
Mcule was founded in 2014. It employs 11 to 50 people.
Where is Mcule based?
Mcule is headquartered in Budapest, Hungary, in the Europe region.
How does Mcule make money?
Three revenue lines are on record. Subscription Plans are the primary driver. The others are compound Sourcing/Procurement and database Downloads.
Who are Mcule's main competitors?
Broad incumbents on record are Enamine, Dotmatics, ChemAxon, Schrödinger and OpenEye Scientific (Cadence Molecular Sciences). Emerging players are Atomwise and Collaborative Drug Discovery (CDD). Direct peers are eMolecules, ChemSpace and MolPort.
Does Mcule have an API?
Yes. Mcule offers an API for programmatic access to its compound database and services. The API documentation is available at doc.mcule.com. Specific details about protocol type, authentication method, rate limits, or versioning are not specified in the source material. Developer documentation is at doc.mcule.com/doku.php?id=api.